TYRVAYA Drug Patent Profile

Which patents cover Tyrvaya, and when can generic versions of Tyrvaya launch?

Tyrvaya is a drug marketed by Oyster Point Pharma and is included in one NDA. There are twelve patents protecting this drug and one Paragraph IV challenge.

This drug has forty-three patent family members in twenty countries.

The generic ingredient in TYRVAYA is varenicline tartrate. There are twelve drug master file entries for this compound. Thirty-two suppliers are listed for this compound. Additional details are available on the varenicline tartrate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Tyrvaya

A generic version of TYRVAYA was approved as varenicline tartrate by PH HEALTH on August 11^th, 2021.

Summary for TYRVAYA

International Patents:	43
US Patents:	12
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	104
Clinical Trials:	2
Patent Applications:	242
Drug Prices:	Drug price information for TYRVAYA
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for TYRVAYA
What excipients (inactive ingredients) are in TYRVAYA?	TYRVAYA excipients list
DailyMed Link:	TYRVAYA at DailyMed

See drug prices for TYRVAYA

Recent Clinical Trials for TYRVAYA

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Duke University	Phase 4
Oyster Point Pharma, Inc.	PHASE4

See all TYRVAYA clinical trials

Pharmacology for TYRVAYA

Drug Class	Cholinergic Receptor Agonist Partial Cholinergic Nicotinic Agonist
Mechanism of Action	Cholinergic Agonists Partial Cholinergic Nicotinic Agonists

Paragraph IV (Patent) Challenges for TYRVAYA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
TYRVAYA	Nasal Spray	varenicline tartrate	0.03 mg/spray	213978	1	2023-04-21

US Patents and Regulatory Information for TYRVAYA

TYRVAYA is protected by twelve US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Oyster Point Pharma	TYRVAYA	varenicline tartrate	SPRAY;NASAL	213978-001	Oct 15, 2021		RX	Yes	Yes
Oyster Point Pharma	TYRVAYA	varenicline tartrate	SPRAY;NASAL	213978-001	Oct 15, 2021		RX	Yes	Yes
Oyster Point Pharma	TYRVAYA	varenicline tartrate	SPRAY;NASAL	213978-001	Oct 15, 2021		RX	Yes	Yes
Oyster Point Pharma	TYRVAYA	varenicline tartrate	SPRAY;NASAL	213978-001	Oct 15, 2021		RX	Yes	Yes			Y
Oyster Point Pharma	TYRVAYA	varenicline tartrate	SPRAY;NASAL	213978-001	Oct 15, 2021		RX	Yes	Yes
Oyster Point Pharma	TYRVAYA	varenicline tartrate	SPRAY;NASAL	213978-001	Oct 15, 2021		RX	Yes	Yes			Y
Oyster Point Pharma	TYRVAYA	varenicline tartrate	SPRAY;NASAL	213978-001	Oct 15, 2021		RX	Yes	Yes

International Patents for TYRVAYA

See the table below for patents covering TYRVAYA around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2015336216
Australia	2020213351
Brazil	112017008097
Brazil	122022025737
Canada	2965129
China	107106542
China	111956650

Supplementary Protection Certificates for TYRVAYA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1044189	08C0039	France		PRODUCT NAME: VARENICLINE OU L?UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES, NOTAMMENT LE TARTRATE; REGISTRATION NO/DATE IN FRANCE: EU/1/06/360/001 DU 20060926; REGISTRATION NO/DATE AT EEC: EU/1/06/360/001 DU 20060926
1044189	SPC/GB08/034	United Kingdom		PRODUCT NAME: VARENICLINE, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, INCLUDING THE TARTRATE SALT; REGISTRATION NO/DATE: EU/1/06/360/001 - 010 20060928

TYRVAYA (fostemsavir?) Market Dynamics and Financial Trajectory: exclusivity, generic/biosimilar risk, and revenue outlook

Last updated: July 27, 2026

TYRVAYA is a targeted, brand-led specialty ophthalmic/inhaled respiratory niche therapy with strong payer scrutiny, high gross-to-net compression risk typical of branded specialty products, and a financial trajectory that is dominated by volume durability, formulary access, and seasonal/disease incidence patterns.

What is TYRVAYA and why does market access drive its financial trajectory?

TYRVAYA is a branded therapy developed and marketed for dry eye disease driven by neuro-sensory pathways, with commercialization shaped by (1) ophthalmology prescribing behavior, (2) coverage policy controls, and (3) competing branded agents and device-driven pathways. Revenue trajectory is therefore less about trial-level efficacy messaging and more about sustained access across large pharmacy benefit (PBM) formularies and specialty distribution channels.

Which patient segments and care settings determine demand?

Demand is set primarily by:

• Ophthalmology clinics managing ocular surface disease.
• Specialty pharmacy fulfillment versus traditional retail, depending on payer design.
• Re-treatment frequency driven by symptom recurrence patterns and clinician selection.

What payer dynamics most affect net sales?

The product’s financial model is typically exposed to:

• Step edits, prior authorization, and documentation requirements.
• Quantity limits if payers cap treatment duration.
• Preferencing or “preferred” positioning versus competing branded dry-eye options.

How strong is TYRVAYA’s pricing and gross-to-net exposure?

The branded specialty profile usually produces elevated gross-to-net through:

• Manufacturer rebates tied to formulary tiers.
• Contracting outcomes with PBMs and integrated delivery networks.
• Indication or line-of-therapy restrictions.

What does that imply for profitability and operating leverage?

As volume grows:

• Fixed costs in sales and marketing scale better than rebates and admin fees.
• The marginal contribution depends on whether formulary placement stays stable.
• Operating leverage improves if access expands faster than rebate rates.

What is the competitive landscape for TYRVAYA, and how does it impact revenue growth?

TYRVAYA competes within the broader dry eye therapeutic ecosystem that includes:

• Other prescription eye drops (anti-inflammatory, tear-stimulating, lubricants with unique actives).
• Device and procedure-adjacent interventions used by ophthalmology practices.
• Over-the-counter (OTC) lubricants acting as substitutes when payers tighten criteria.

How do competitors affect prescribing behavior?

Competitors influence:

• Formulary design and prior authorization stringency.
• Switching rates from older prescription agents once a patient becomes stable.
• Clinical guideline adherence and practice-level preference patterns.

When does TYRVAYA lose exclusivity and what does that mean for revenue risk?

Revenue risk timing is anchored by:

• Patent expiration for the listed brand claims in the FDA Orange Book.
• Exclusivity expirations tied to regulatory milestones.
• Potential entry windows for generic versions depending on the regulatory pathway.

Complete exclusivity and patent-expiration mapping requires the Orange Book record for TYRVAYA (active ingredient, dosage form, NDA number, listed patents, and expiries). Without that record, a precise “date-to-entry” schedule cannot be produced in a way that is actionable for litigation, licensing, or investment decisions.

What patent estate protects TYRVAYA, and which expiration dates matter to generics?

A defensible risk assessment requires:

• Which patents are listed for TYRVAYA in the Orange Book (drug substance, drug product, formulation, method-of-use, and manufacturing).
• Expiration dates and patent-term adjustment (PTA) overlays.
• Any orphan pediatric exclusivity or other extensions.

A complete count of covering patents and their expiration dates cannot be stated without the Orange Book listing details for TYRVAYA.

What generic entry risks exist for TYRVAYA (Paragraph IV, 505(b)(2), or ANDA)?

Generic entry risk depends on:

• Whether TYRVAYA’s claims are enforceable and whether an ANDA applicant can certify around them.
• Whether the dosage form and formulation patents block straightforward bioequivalence.
• The feasibility of a 505(b)(2) “switch” that changes formulation or delivery while preserving clinical performance.

A statement on likely entry routes (ANDA vs 505(b)(2)) and Paragraph IV likelihood requires Orange Book method-of-use and formulation patent coverage details.

What is the Orange Book status of TYRVAYA?

Orange Book status determines:

• Listed patent numbers and patent types.
• Remaining exclusivity.
• The certification landscape for generic filers.

The Orange Book status cannot be reproduced without the specific NDA identifier and listed patent dataset for TYRVAYA.

What litigation and settlements affect TYRVAYA’s financial forecast?

Branded ophthalmology and dry-eye categories often see:

• Patent infringement actions tied to formulation and method-of-use.
• Stay outcomes after patent litigation (automatic stays or negotiated settlement dates).
• Calendar pressure on generic launch scheduling.

No TYRVAYA-specific litigation timeline can be provided without case captions, court dockets, and settlement dates tied to the NDA and patent numbers.

What is the regulatory status of TYRVAYA (FDA approvals, labeling, and exclusivity basis)?

TYRVAYA’s regulatory trajectory is typically defined by:

• NDA approval date(s).
• Labeling expansion history.
• Exclusivity periods tied to new chemical entity, new clinical investigation, or orphan-related pathways (if applicable).

A precise regulatory timeline requires TYRVAYA’s NDA and supplement record.

How does TYRVAYA compare with other dry eye therapies on time-to-market and commercialization?

Revenue trajectory comparisons depend on:

• Payer coverage onset and contracting speed.
• Differentiated endpoints in label versus competitors.
• Formulary persistence after launch maturity.

A quantified peer comparison (market share, sales curves, launch timing) cannot be produced without specifying the competitor set and TYRVAYA’s verified historical sales datapoints.

What commercialization levers most influence TYRVAYA’s next 12 to 36 months?

For branded specialty ophthalmic therapies, forward performance is most sensitive to:

• Formulary expansions and reduced prior authorization friction.
• Specialty pharmacy contracting (rebates and channel mix).
• Retention of prescribing among ophthalmologists and optometrists who manage ocular surface disease.
• Seasonal and chronicity effects on re-order patterns.

What internal KPIs typically predict revenue inflection?

• New prescriber count and repeat-therapy rate.
• Share of prescriptions by formulary tier.
• Net price realization after rebates.
• Claims trend in covered lives.

What does the financial trajectory depend on: volume, price, or mix?

A specialty branded product’s revenue typically breaks down into:

• Volume: prescriptions filled and adherence/re-treatment behavior.
• Price: WAC vs net price, driven by contracts and rebates.
• Mix: geography, payer segment, and clinic channel.

Without TYRVAYA’s verified net sales history and payer mix, a numeric decomposition cannot be produced.

Key takeaways

• TYRVAYA’s financial trajectory is primarily driven by formulary access durability, PBM contracting outcomes, and prior authorization friction rather than by clinical efficacy messaging alone.
• Gross-to-net exposure is the key swing factor for margin, making net price realization and rebate governance central to profitability.
• Revenue downside risk is calendar-driven (patent and exclusivity expirations) and event-driven (litigation and settlement stays).
• A date-specific generic and exclusivity runway requires TYRVAYA’s Orange Book listing (NDA number, listed patents, and expiration dates), plus any litigation docket data.

FAQs

1) How does TYRVAYA gross-to-net typically trend in specialty ophthalmic categories?
Modeled to decline if formulary access improves faster than rebate rates; worsens when payers tighten utilization management.

2) What payer coverage patterns matter most for TYRVAYA?
PBM formulary tier stability, prior authorization criteria consistency, and specialty pharmacy preference status.

3) What generic entry scenarios are most likely for TYRVAYA?
Scenarios hinge on whether formulation and method-of-use patents are listed and whether an applicant can avoid them without a patent carve-out.

4) How do litigation stays impact TYRVAYA’s revenue forecast?
Settlement-triggered stays delay launch timing and reduce near-term price erosion risk.

5) What near-term commercial signals indicate TYRVAYA momentum?
New prescriber growth, retention/re-treatment rates, and net price realization versus prior quarters.

---

References (APA)

No sources were provided in the prompt, and no TYRVAYA-specific Orange Book, FDA, or financial filings were cited.

DrugChatter Q&A for TYRVAYA

Tyrvaya dry eye disease treatment?
Tyrvaya nasal spray where to buy?
Tyrvaya nasal spray price?
Tyrvaya cost without insurance?
Tyrvaya nasal spray generic?